Business
Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth
On August 28, 2025, Viva Biotech Holdings Group ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that the Group's revenue amounted to RMB831.9 million, and the Group's gross profit of RMB339.4 million. The Group's gross profit margin was 40.8%, an increase of 6.3 percentage points from the corresponding period of last year, primarily attributable to the optimization and adjustment of Langhua's business structure, improved operational efficiency in CRO business, and c
About this update from Viva Biotech Holdings
[{"type":"text","content":"Results Highlights for Interim Results ended 30 June 2025","length":57,"tagName":"p"},{"type":"text","content":"Revenue reached RMB831.9 million","length":32,"tagName":"p"},{"type":"text","content":"Gross profit amounted to RMB339.4 million","length":41,"tagName":"p"},{"type":"text","content":"Gross profit margin was 40.8%, an increase of 6.3 percentage point","length":66,"tagName":"p"},{"type":"text","content":"Net profit amounted to RMB148.6 million, increased by 3.1% YoY","length":62,"tagName":"p"},{"type":"text","content":"Adjusted non-IFRS net profit reached RMB183.5 million, increased by 9.1% YoY","length":76,"tagName":"p"},{"type":"text","content":"SHANGHAI, Aug. 28, 2025 /PRNewswire/ -- On August 28, 2025, Viva Biotech Holdings Group ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that the Group's revenue amounted to RMB831.9 million, and the Group's gross profit of RMB339.4 million. The Group's gross profit margin was 40.8%, an increase of 6.3 percentage points from the corresponding period of last year, primarily attributable to the optimization and adjustment of Langhua's business structure, improved operational efficiency in CRO business, and contributions from new business segments. In the first half of 2025, the Group's net profit amounted to RMB148.6 million, representing a year-over-year increase of 3.1% compared to the net profit of RMB144.2 million for the corresponding period of last year; adjusted non-IFRS net profit improved from RMB168.2 million for the corresponding period of last year to an adjusted non-IFRS net profit of RMB183.5 million, representing a year-on-year increase of nearly 9.1%. This was mainly driven by the positive growth in both revenue from CRO business and adjusted non-IFRS net profit, as well as enhanced profitability resulting from the optimization of Langhua's business structure.","length":1275,"tagName":"p"},{"type":"text","content":"CRO Revenue Returned to Positive Growth, with a Significant Recovery in Domestic Growth","length":87,"tagName":"p"},{"type":"text","content":"In the first half of 2025, the Company's revenue from CRO business increased by approximately 9.6% from RMB385.9 million for the corresponding period of last year to RMB422.8 million, and the adjusted gross profit from such busi...